Physician profile
Nan Jiang
NPI 1316207244
$29,507.94
in general payments reported to CMS, 2019-2025
13 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,414 · 2020: $1,085 · 2021: $2,458 · 2022: $8,598 · 2023: $6,179 · 2024: $697 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,250 · Food and Beverage: $2,145 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,852 · Consulting Fee: $1,598 · Education: $76.99 · Travel and Lodging: $31.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,250.00 |
| Food and Beverage | $2,145.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,852.16 |
| Consulting Fee | $1,597.50 |
| Education | $76.99 |
| Travel and Lodging | $31.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $12,596.72 | 2019-2024 | Ultomiris |
| Csl Behring | $6,959.06 | 2019-2025 | Hizentra, Privigen |
| Argenx US, INC. | $2,722.47 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amylyx Pharmaceuticals, INC. | $2,342.46 | 2023 | Relyvrio |
| Akcea Therapeutics, INC. | $1,811.91 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $1,773.33 | 2023 | |
| Ucb, INC. | $801.36 | 2021-2025 | Rystiggo, Zilbrysq |
| Cadwell Industries, INC | $170.00 | 2024 | |
| Alnylam Pharmaceuticals INC. | $125.00 | 2025 | Amvuttra |
| Biogen, INC. | $95.03 | 2020 | |
| Janssen Biotech, INC. | $76.99 | 2025 | |
| Amgen INC. | $22.29 | 2024 | Uplizna |
| Abbvie INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.